Astellas Pharma (Astellas Pharma) Accounts Receivable : $3,445 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Astellas Pharma's accounts receivables for the quarter that ended in Dec. 2023 was $3,445 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Astellas Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 107.26.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Astellas Pharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-4.24.

Astellas Pharma Accounts Receivable Historical Data

The historical data trend for Astellas Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Accounts Receivable Chart

Astellas Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Accounts Receivable

Get a 7-Day Free Trial

3,082.73

3,223.28

3,157.14

3,225.42

3,201.79

Astellas Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															3,344.89	3,201.79	3,271.85	3,300.03	3,444.62

Astellas Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Astellas Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Astellas Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3444.616	/	2930.46	*	91
=	107.26

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Astellas Pharma's accounts receivable are only considered to be worth 75% of book value:

Astellas Pharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1982.449	+	0.75 * 3444.616	+	0.5 * 1569.507	-	12956.019
-	0	-	0)	/	1792.99
=	-4.24

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Astellas Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (Astellas Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Mexico 4503:Japan YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.